<?xml version="1.0" encoding="UTF-8"?>
<p id="para130">Eligible participants were healthy adults aged between 18 and 50 years; able to provide consent to participate and having signed an informed consent form; able and willing to comply with all study procedures; women of childbearing potential agreed to either remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, or spermicide) or have a partner who was sterile from enrolment to 3 months following the last injection, or had a partner who was unable to induce pregnancy; sexually active men who were considered sexually fertile must have agreed to use either a barrier method of contraception during the study, and agreed to continue the use for at least 3 months following the last injection, or have a partner who was permanently sterile or unable to become pregnant; normal screening electrocardiogram (ECG) or screening ECG with no clinically significant findings; screening laboratory findings must be within normal limits or be grade 0â€“1 findings; no history of clinically significant immunosuppressive or autoimmune disease; not currently or within the previous 4 weeks taking immuno-suppressive drugs (excluding inhaled, topical skin, or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose &lt;20 mg/day); and willing to allow storage and future use of samples for MERS coronavirus-related research.</p>
